Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Drops By 21.6%

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 101,900 shares, a decrease of 21.6% from the January 15th total of 130,000 shares. Approximately 0.2% of the company's stock are short sold. Based on an average daily volume of 85,200 shares, the days-to-cover ratio is currently 1.2 days.

Hedge Funds Weigh In On Alpha Tau Medical

Several large investors have recently modified their holdings of the stock. Northern Trust Corp raised its position in shares of Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after acquiring an additional 25,770 shares in the last quarter. Renaissance Technologies LLC increased its stake in Alpha Tau Medical by 188.7% during the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock worth $127,000 after buying an additional 26,800 shares in the last quarter. Finally, Levin Capital Strategies L.P. lifted its position in Alpha Tau Medical by 2.3% during the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company's stock worth $975,000 after buying an additional 7,189 shares in the last quarter. Institutional investors own 2.65% of the company's stock.

Alpha Tau Medical Trading Down 2.9 %

DRTS stock traded down $0.09 during trading on Wednesday, reaching $2.99. The stock had a trading volume of 49,733 shares, compared to its average volume of 124,582. Alpha Tau Medical has a 52 week low of $1.75 and a 52 week high of $4.39. The stock's 50 day moving average is $3.39 and its two-hundred day moving average is $2.71. The firm has a market cap of $209.06 million, a PE ratio of -6.95 and a beta of 0.83.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Alpha Tau Medical in a research note on Friday, November 22nd.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.